Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

evobrutinib

Biogen Idec building

Plegridy approval underlines Biogen Idec’s dominance in MS

And Tecfidera boosts pharma company’s second quarter financial results

- PMLiVE

MS sailing challenge comes to UK

Oceans of Hope yacht has crew of people with multiple sclerosis and is supported by Biogen Idec

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

- PMLiVE

Merck Serono to offer innovation grants

Will provide funding of €20m for research and med ed projects

- PMLiVE

Erbitux betters Avastin in bowel cancer subgroup

Data backs Merck KGaA drug over Roche’s rival in RAS wild-type metastatic colorectal cancer

- PMLiVE

Merck KGaA furthers antibody ambitions in cancer

Signs deal with Mersana to develop antibody-drug conjugates

- PMLiVE

Merck KGaA drops Ono-partnered multiple sclerosis drug

Decides phase III candidate ceralifimod isn't worth its continued investment

National Institute for Health and Care Excellence NICE logo

NICE backs reimbursement of Sanofi’s MS drug Lemtrada

Final guidance opens doors for use on NHS in England and Wales

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

Roche - Basel

Roche and Merck boost manufacturing capacity

Pharma companies invest in European facilities

- PMLiVE

Merck KGaA appoints new CFO

Marcus Kuhnert joins from consumer goods company Henkel

- PMLiVE

New Novartis MS app will turn up the heat on its rivals

Patients can use SymTrac iPhone app to track symptoms and relapses on their current treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links